Pneumonia in Children

Overview & Definition

Pneumonia in children is inflammation of the lung parenchyma, typically of infectious origin, producing cough, fever, respiratory distress (tachypnoea, indrawing, grunting, nasal flaring, head nodding), and parenchymal infiltrates on imaging.^[24]

It is the leading infectious cause of death in children under 5 worldwide, ahead of acute gastroenteritis, malaria, and measles. The disease burden is concentrated in sub-Saharan Africa and South Asia, where access to vaccines, antibiotics, oxygen, and timely care is constrained.^[1][2]

Clinical definition. In hospital and high-resource settings, pneumonia is a clinical-radiographic syndrome: fever, cough, tachypnoea, focal respiratory signs (crepitations, dullness, bronchial breathing, wheeze), and a new parenchymal opacity on chest X-ray. In low-resource and primary-care settings, where chest X-ray is unavailable, the WHO operational definition is used:^[5]

"Pneumonia = cough or difficulty breathing plus fast breathing for age."^[24]

This single bedside rule has underpinned two decades of reduction in pneumonia mortality at first-level facilities and is the framing every NEET-PG/INICET candidate must know.^[24]

Aetiological framing. Pneumonia is caused by a wide range of viruses, bacteria, atypical organisms, and (rarely) parasites. The organism varies sharply by age, and the organism dictates the management (typical bacteria need a beta-lactam; atypical organisms need a macrolide; influenza needs a neuraminidase inhibitor if within 48 h).^[5]

The disease is preventable in most cases. Pneumococcal conjugate vaccine (PCV10/PCV13), Hib conjugate vaccine, measles vaccination, annual influenza vaccination, exclusive breastfeeding for 6 months, hand hygiene, smoke-free indoors, and reduction of indoor air pollution are the WHO-anchored prevention pillars.^[11][12][13]

Classification

Pneumonia in children is classified along three clinically useful axes: severity (the most important for treatment), pathology (lobar vs bronchopneumonia vs interstitial), and aetiology (typical bacterial, atypical, viral).^[13]

By severity — WHO (the operational gold standard)

By pathology

By aetiology — typical, atypical, viral

^[17]

Enlarge

By age — the most useful clinical axis

Epidemiology & Risk Factors

Global burden

Pneumonia has been the leading infectious killer of children under 5 for decades. The GBD 2019 study estimates ~700,000 under-5 deaths annually attributable to lower respiratory infections (LRIs) — about 14% of all under-5 deaths globally — with the bulk falling in sub-Saharan Africa and South Asia.^[2][3]

^[5]

Trend over time

Under-5 pneumonia mortality has fallen substantially over the past three decades — from over 2 million/year in 1990 to ~700,000/year by 2019 — driven by:^[24]

• Conjugate vaccines — PCV, Hib — the single largest biomedical lever.^[11][12][22]
• Expanded oxygen access — universal pulse oximetry and oxygen concentrators at first-level facilities.^[24]
• Standardised case management (WHO IMCI/IMNCI) — amoxicillin for WHO pneumonia.^[7][8][24]
• Improved nutrition — exclusive breastfeeding for 6 months, micronutrient supplementation, and reduction of severe acute malnutrition.
• Socioeconomic change — urbanisation, clean-fuel cooking, reduced household crowding.

Even so, the burden plateaued in many countries during the COVID-19 era and health-system disruption; the GBD 2021 update shows a rebound of LRIs to levels comparable to pre-pandemic estimates.^[3]

Aetiological epidemiology by age

^[11]

Vaccine impact

The conjugate vaccines have transformed childhood pneumonia epidemiology. The Watt 2009 Lancet analysis estimated Hib caused ~8% of pneumonia deaths in children under 5 globally (in the pre-vaccine era); after Hib conjugate introduction, Hib disease in vaccinated populations collapsed.^[10][14] PCV10/PCV13 has produced parallel drops in invasive pneumococcal disease and radiologically confirmed pneumonia in vaccinated cohorts.^[11][12] The Hanquet 2019 Thorax study confirmed a substantial indirect (herd) effect on older unvaccinated cohorts across Europe.^[22]

Risk factors

Child-level risk factors:^[2]

• Age: peak incidence 2-12 months; mortality highest in 2-12 month age band.
• Prematurity / low birth weight.
• Non-breastfed, or exclusively breastfed under 6 months.
• Severe acute malnutrition (SAM) — multiplies pneumonia mortality.
• Immunodeficiency — congenital, HIV, chemotherapy, transplantation.
• Chronic lung disease of prematurity (BPD).
• Congenital heart disease, especially cyanotic.
• Sickle-cell disease / functional asplenia — risk of pneumococcal sepsis.
• Recurrent aspiration — neurodisability, GERD, neuromuscular disorders.
• Wheezing — concurrent asthma or viral-triggered wheeze.^[3]

Household / environmental risk factors:^[2]

• Indoor air pollution — solid-fuel cooking (biomass), second-hand tobacco smoke.
• Household crowding.
• Lack of immunisation.
• Lower socioeconomic status — multiple pathways (poor nutrition, crowding, lower care-seeking).^[2]

Care-seeking factors:^[2]

• Delayed presentation.
• Inadequate access to oxygen and pulse oximetry.
• Self-medication or inappropriate antibiotics.^[2]

Pathophysiology

The two archetypes

The behaviour and treatment of childhood pneumonia are dominated by two anatomical-pathological archetypes — alveolar consolidation (typical bacterial) and small-airway/airway-centred interstitial disease (viral and atypical). They have different microanatomy, different physiology, different imaging, and different first-line antibiotic rationale.^[7]

Enlarge

Bacterial alveolar consolidation

The S pneumoniae model best illustrates the cascade:^[11]

1. Nasopharyngeal colonisation — pneumococcus colonises the upper airways in roughly 20-40% of healthy children at any time. Colonisation is harmless unless the host's defences fail.
2. Micro-aspiration — overflow into the lower respiratory tract occurs physiologically; effective mucociliary clearance and alveolar macrophage function normally contain it.
3. Failure of defence — viral upper-respiratory infection (especially influenza), malnutrition, immune suppression, or no prior immunological experience (infants) allow the organism to establish in alveoli.
4. Alveolar exudate — exudation of neutrophils, fibrin and red cells into the alveolar air space; this consolidates the alveolus and replaces air with fluid/cells.
5. Spread — through the pores of Kohn and canals of Lambert within the lobe (lobar) or via centrilobular airways (bronchopneumonia).
6. Impaired gas exchange — perfusion continues but ventilation drops in consolidated regions → shunting → hypoxaemia.
7. Systemic signs — pyrogens (IL-1, IL-6, TNF) drive fever, rigors, anorexia, tachycardia.^[1]

Viral bronchiolitis and viral pneumonia

The RSV model illustrates viral lower respiratory disease:^[1]

1. Nasopharyngeal inoculation → viral replication in ciliated epithelial cells.
2. Cellular cytotoxicity and immune response — epithelial necrosis, submucosal oedema, lymphocytic infiltrate.
3. Mucus hypersecretion and peribronchiolar inflammation — combine with exudate in the small airways.
4. Small-airway plugging — produces air trapping and hyperinflation distal to plugs (ball-valve mechanism).
5. Interstitial mononuclear infiltrate — interstitial thickening; alveolar air preserved.
6. Wheeze and crackles — mixed obstruction and inflammation.
7. Hypoxaemia — primarily V/Q mismatch with air-trapping; alveolar collapse in more severe disease.^[5]

Viral infection is also the most important risk for secondary bacterial pneumonia: influenza damages airway epithelium and impairs mucociliary clearance, allowing bacterial superinfection (Streptococcus pneumoniae, Staphylococcus aureus) 5-10 days into the illness.^[5]

Atypical (interstitial) pneumonia

Mycoplasma pneumoniae binds to sialic acid residues on respiratory epithelium via the P1 adhesin, causes ciliary dysfunction, and produces a subepithelial lymphocytic infiltrate. Bacteria are intracellular and cannot be cultured on routine media, which is why macrolides (which concentrate intracellularly) are required.^[16]

The clinical manifestation is subacute: dry cough, low-grade fever, headache, and the x-ray-physical dissociation — interstitial infiltrates on imaging disproportionate to the physical findings.^[21]

Necrotising pneumonia — the dangerous complication

Necrotising pneumonia is parenchymal necrosis with multiple thin-walled cavities, pneumatoceles and frequently empyema. It is most commonly caused by:^[21]

• Streptococcus pneumoniae serotype 19A (not covered by older PCV7),
• Staphylococcus aureus, particularly Panton-Valentine leukocidin (PVL)-positive strains — epidemic in parts of Europe and elsewhere;^[21]
• Less commonly, H. influenzae and Klebsiella.

Complications pathophysiology

Clinical Presentation

The textbook triad is cough, fever, and tachypnoea — but infants often present atypically, and older children may have subtle features. A complete history must establish:^[22]

• Onset and tempo — abrupt = typical bacterial; gradual = atypical/viral.
• Cough character — dry, productive; paroxysms ± whoop; post-tussive vomiting (pertussis).
• Fever — height and pattern; rigours suggest typical bacterial.
• Breathing difficulty — fast breathing, indrawing, grunting, nasal flaring, head nodding, accessory muscle use.
• Feeding / hydration — decreased feeding, vomiting, reduced wet nappies, lethargy.
• Immunisation history — RSV, influenza, PCV, Hib, measles, pertussis, BCG.
• Exposure — household illness, daycare, family TB, fumes/biomass cooking.
• Past medical history — prematurity, BPD, congenital heart disease, recurrent pneumonia (immunodeficiency, malformation, aspiration).
• Drugs / allergies, especially prior antibiotic exposure.
• Skin rash — scarlatiniform (S aureus scarlet fever), maculopapular (measles), vesicular (varicella), urticarial.^[21]

Cardinal signs of respiratory distress

Typical pattern by aetiology

Chlamydia trachomatis in young infants (4-12 weeks)

Neonatal chlamydial pneumonia follows vertical Chlamydia trachomatis transmission: infants born to mothers with untreated infection can develop both conjunctivitis and pneumonia despite ocular prophylaxis — erythromycin or tetracycline ointment at birth does not reduce neonatal chlamydial conjunctivitis or the associated respiratory infection (pneumonia still developed in 0-4% of prophylaxed infants in pooled prospective data). The effective strategy is antenatal screening and treatment of the mother.^[30]

Staph aureus pneumonia (and PVL-positive)

• Post-influenza superinfection (5-10 days into influenza).
• Abrupt onset, high fever, pleuritic pain, rapidly progressive.
• Pneumatoceles, empyema, necrotising pneumonia, pyopneumothorax.
• PVL-positive strains in particular progress rapidly with necrotic lung lesions and are highly lethal if not treated aggressively.^[21]

Bordetella pertussis

• Paroxysmal cough ending in inspiratory whoop, post-tussive vomiting, subconjunctival haemorrhage.
• Apnoea as the cardinal feature in infants under 6 months.
• Peripheral blood: marked lymphocytosis (often over 20 ×10⁹/L).
• Confirm with nasopharyngeal swab PCR.
• Treat with azithromycin or erythromycin.^[7]

Measles pneumonia

• Measles pneumonia: vitamin A deficiency is a recognised risk factor for severe measles, and pneumonia is the measles complication that drives mortality risk.
• Vitamin A (WHO recommendation): an oral dose of 200,000 IU per day for 2 days (100,000 IU in infants) for children with measles in areas where vitamin A deficiency may be present.
• Two doses of 200,000 IU reduced overall mortality by 64% (RR 0.36) and pneumonia-specific mortality by 67% (RR 0.33) versus placebo in randomised trials — a single dose showed no benefit.^[25]

Atypical presentations — the examiner's favourites

Examining the chest in a child

1. Look — tachypnoea, indrawing, nasal flaring, head nodding, asymmetry of chest expansion, scars (chest tubes), central cyanosis, clubbing (chronic pneumonia — consider bronchiectasis, immunodeficiency).
2. Feel — tracheal position (push = effusion/mass; pull = collapse), chest expansion (decreased on consolidated side), tactile vocal fremitus (increased over consolidation, decreased over effusion).
3. Percuss — dull (consolidation, effusion); hyper-resonant (pneumothorax, large consolidation with air trapping).
4. Listen — crackles (crepitations) over consolidation; bronchial breathing with increased vocal resonance = consolidation; absent breath sounds and dullness = effusion; wheeze = bronchospasm (viral, foreign body, asthma).^[24]

Differential Diagnosis

The "pneumonia" label is potentially applied to many non-pneumonic conditions. A structured differential is mandatory because missing it changes outcome.^[7]

Clinical & Bedside Assessment

The WHO approach is the operational gold standard, and every examiner will expect it reproduced verbatim.^[24]

^[5]

WHO assessment sequence (use this at first-level facilities and in any exam):^[24]

1. CHECK FOR DANGER SIGNS — if any, the child has VERY SEVERE pneumonia. Move to emergency care.
2. COUNT respirations over a full minute (a young infant's RR is labile; count again if borderline).
3. Look for chest indrawing — subcostal/intercostal retractions on inspiration with the chest wall visibly sinking between/below the ribs.
4. Listen for grunting — soft, audible expiratory vocalisation in young infants (a sign of impending respiratory failure).
5. Stridor, wheeze, or general danger signs (vomiting everything, convulsions, lethargy/unconsciousness).^[24]

WHO severity classification — reproduced exactly

Additional bedside findings that matter

• Pulse oximetry: target 94-98% in non-cardiac children; <90% triggers oxygen supplementation.
• Capillary refill >2 s — coexisting shock, poor perfusion.
• Hydration — sunken eyes, reduced tears, dry mucosa, decreased urine output, weight change.
• Nutritional status — weight, mid-upper-arm circumference (MUAC, SAM if <11.5 cm in 6-59 months).
• Temp — fever >38.5 °C or hypothermia <36 °C.
• Chest signs — see Examining the chest above.^[7]

Investigations

Most childhood pneumonia is a clinical diagnosis. Investigations are risk-stratified.^[24]

Imaging

^[5]

Microbiology

^[5]

Bloods

• Most childhood pneumonia is diagnosed clinically — no single blood test confirms or excludes it; investigations serve to define aetiology and to risk-stratify the sick child.
• Even clinical signs are individually imperfect: the pooled sensitivity of WHO age-related fast breathing was 0.62 and of lower chest wall indrawing 0.48 for radiological pneumonia — combinations of features outperform any single sign.^[28]
• Hypoxaemia (SpO2 under 90%) is the bedside measure that matters most: it was present in 40% of children hospitalised with WHO-defined severe pneumonia in a Dhaka cohort and was the strongest predictor of death (adjusted OR 11.1) and of clinical deterioration (adjusted OR 5.9).^[27]

Other

• Urine pneumococcal antigen and Legionella urinary antigen — older child, atypical presentation, outbreak setting.
• Serology — cold agglutinins and Mycoplasma IgM (4-fold rise, or single positive IgM with clinical picture).
• Bronchoscopy with bronchoalveolar lavage (BAL): immunocompromised, ventilator-associated, refractory pneumonia.
• ECG and echocardiogram: when myocarditis or pericardial effusion is considered.
• Sputum AFB and GeneXpert MTB/RIF: when TB is suspected.^[17]

Management — Resuscitation

The first minutes of very severe pneumonia are about airway, breathing, and circulation — ABCDE — not antibiotics.^[5]

^{[26] [27] [8]}

Oxygen delivery — escalation ladder

^{[26] [27]}

Management — Definitive & Stepwise

The pillars are (1) oxygen, (2) appropriate antibiotic, (3) supportive care, (4) fluids + nutrition, (5) monitoring, and (6) prevention of transmission. For complicated disease, (7) procedural management of empyema, (8) necrotising pneumonia care, and (9) follow-up imaging.^[13]

Empirical antibiotic selection — by severity

^{[8] [8] [7] [25] [26]}

Atypical-pathogen consideration

When a school-age child has persistent dry cough, bilateral wheeze or crackles, or inadequate response to a beta-lactam at 48-72 hours, add a macrolide or switch to a macrolide:^[16][17][23]

• Mycoplasma pneumoniae was the most commonly detected bacterium among children aged 5 years and over hospitalised with CAP (8% of all admissions; median age 7 years; 26% had pleural effusion; macrolide resistance only 4%).^[17]
• Extrapulmonary complications involving all major organ systems occur via direct invasion and/or autoimmune response — sometimes of greater severity and clinical importance than the respiratory illness itself; macrolides are effective therapy for M. pneumoniae infection.^[16]

Supportive care — the rest of the bundle

^[27]

Complications — when the bundle isn't enough

Pleural effusion and empyema — the classic local complications of complicated pneumonia.^[21]

• Complicated pneumonia should be suspected in any child not responding to appropriate antibiotics within 48-72 h — think parapneumonic effusion, empyema, necrotising pneumonia, lung abscess; the common causative organisms are S pneumoniae and S aureus.^[21]
• Imaging: initial chest radiography plus ultrasound, which can also assess the lung parenchyma and guide drainage.^[21]
• Intrapleural fibrinolysis (MIST2): 3 days of intrapleural tPA + DNase improved radiographic pleural-opacity clearance versus placebo and reduced surgical referral (4% vs 16% at 3 months) — while neither tPA alone nor DNase alone beat placebo.^[19]
• VATS versus chest tube + fibrinolysis: in a paediatric randomised trial (12F chest tube plus 4 mg tPA instillations) there was no difference in days of hospitalisation after intervention, days of oxygen requirement, or days until afebrile.^[18]

Pneumothorax — needle aspiration (2nd intercostal space mid-clavicular line or 4th-5th intercostal space anterior axillary line for paediatric small-bore drains), then small-bore chest drain in the triangle of safety.^[18]

Pneumatocele — usually conservative; serial CXR; intervention only if large and symptomatic.^[18]

Lung abscess — prolonged IV antibiotics (4-6 weeks) targeting anaerobes, S aureus, S pneumoniae; percutaneous drainage if persistent.^[11]

Necrotising pneumonia — prolonged IV antibiotics (often 4-6 weeks) covering S aureus (incl. PVL — vancomycin/linezolid if MRSA), pneumococcus, anaerobes; supportive management; surgical lobectomy rarely needed.^[5]

When to escalate, when to step down

Enlarge

^[8]

Vaccination and prevention

Specific Subtypes & Scenarios

Neonatal pneumonia

Staphylococcal pneumonia (PVL-positive and MSSA)

• Often follows influenza, measles, or post-tonsillectomy.
• Pneumatoceles, empyema, pyopneumothorax, necrotising pneumonia.
• Treat: IV anti-staphylococcal beta-lactam (flucloxacillin) ± vancomycin/linezolid if MRSA; chest drain for empyema; prolonged IV course 4-6 weeks.^[21]

Mycoplasma pneumoniae — rising

• Commonest pathogen in school-age children with community-acquired pneumonia.^[17]
• Can complicate Stevens-Johnson syndrome, cold agglutinin haemolytic anaemia, GBS, polyarthritis.
• Macrolide resistance is rising; consider tetracycline/doxycycline in children >8 years as an alternative.^[16][23]

Tuberculous pneumonia

• Subacute presentation (over 2-4 weeks), weight loss, night sweats, persistent CXR opacity with hilar adenopathy.
• Often primary complex: Ghon focus + hilar lymphadenopathy.
• Diagnosis: clinical + CXR + Tuberculin test (or IGRA in older children) + microbiology (gastric aspirate or BAL GeneXpert MTB/RIF).
• Standard 6-month TB regimen (isoniazid + rifampicin × 6 months; pyrazinamide × 2 months; ± ethambutol).^[7]

Necrotising pneumonia

• Multiple thin-walled cavitations on CXR, persistent fevers despite appropriate antibiotics.
• Common after pneumococcal serotype 19A or PVL-positive S aureus.^[21]
• Management: prolonged IV antibiotics, supportive management, intervention only if severe.

Measles-associated pneumonia

• Post-measles pneumonia contributes to measles mortality, and vitamin A deficiency is a recognised risk factor for severe measles.
• Vitamin A: an oral dose of 200,000 IU per day for 2 days (100,000 IU in infants) — two 200,000 IU doses reduced overall mortality (RR 0.36) and pneumonia-specific mortality (RR 0.33) versus placebo in randomised trials.^[25]

Recurrent pneumonia

Complications & Pitfalls

^[21]

Prognosis & Disposition

Disposition decisions:^[1]

• WHO pneumonia: home after first dose observed; follow-up at 48-72 h and 7 days.
• Severe pneumonia: hospital admission, ward care; HFNC if needed.
• Very severe pneumonia: high-dependency or PICU; intubation if indicated.
• Empyema: surgical/medical ICU level of care depending on drainage approach.
• Necrotising pneumonia: PICU.^[5]

Safety-net advice at discharge:^[24]

• Return immediately if breathing worsens, fever recurs, cannot drink, vomits everything, convulsion, or drowsy.
• Complete the full course of oral antibiotic (typically 5 days for WHO pneumonia; longer if severe).
• Avoid tobacco smoke exposure and indoor air pollution.
• Catch-up immunisations (PCV, Hib, measles, pertussis, influenza) on recovery.
• If recurrent pneumonia, follow-up in clinic with CXR and immunological workup.^[8]

Special Populations

Severe acute malnutrition (SAM)

Pneumonia is one of the largest contributors to SAM mortality. The WHO IMCI protocol for SAM provides specific guidance:^[6]

• In a Dhaka cohort of WHO-defined severe pneumonia, severe acute malnutrition was among the factors assessed for mortality risk — but hypoxaemia was the strongest predictor of death (adjusted OR 11.1); screen every malnourished child with pulse oximetry.^[27]
• In the PERCH site-specific analyses, pneumonia aetiology varied with malnutrition status as well as age, mortality status, severity and HIV status — the malnourished child is not simply a smaller version of the well-nourished one.^[6]

HIV-infected child

The differential widens substantially:^[5]

• Pneumocystis jirovecii pneumonia — the classic opportunistic pneumonia of HIV; co-trimoxazole prophylaxis prevents it, and before ART scale-up prophylaxis reduced morbidity and mortality in children with HIV by preventing bacterial infections, diarrhoea, malaria, and Pneumocystis pneumonia.^[29]
• Co-trimoxazole prophylaxis is recommended for HIV-exposed infants from age 4-6 weeks; WHO recommends long-term prophylaxis for children in settings with a high prevalence of malaria or severe bacterial infections.^[29]

Immunocompromised (transplant, chemotherapy)

• Pre-test for PJP, CMV, RSV, parainfluenza, adenovirus, RSV; broad respiratory viral PCR and BAL routinely.
• Consider empirical co-trimoxazole + broad-spectrum antibacterial + voriconazole/echinocandin if febrile neutropenic.^[1]

Sickle-cell disease

• Pneumococcal sepsis is a major risk (functional asplenia); cover with empirical ceftriaxone ± vancomycin.
• Vaccination: PCV, PPSV23, Hib, influenza annually; daily penicillin prophylaxis <5 years.^[22]

Cystic fibrosis

• Recurrent pneumonia with Pseudomonas or Staph aureus.
• Chest CT, sweat test.
• Airway clearance and chronic antibiotics as per CF team.^[5]

Neurodisability / aspiration

• Consider positioning, thickened feeds, H2-blockers or PPIs for GERD, swallow assessment.
• Recurrent aspiration with right upper-lobe involvement.^[1]

Congenital cyanotic heart disease

• Increased pneumonia risk with poor perfusion; the myocardium is at risk.
• Avoid fluid overload.^[5]

Evidence, Guidelines & Regional Differences

Landmark evidence

• Hazir Lancet 2008 (SAT trial): in 2037 children aged 3-59 months with severe pneumonia across 7 Pakistani sites, home 5-day oral amoxicillin 80-90 mg/kg/day in two doses was equivalent to initial hospitalisation with parenteral ampicillin 100 mg/kg/day in four doses — supporting outpatient treatment of severe pneumonia in low-resource settings.^[8]
• Hazir ADC 2007: the double-dose RCT compared 45 vs 90 mg/kg/day × 3 days — day-5 failure 4.5% vs 5.7% (no significant difference) — dose-doubling adds nothing.^[7]
• Mulholland Lancet 1997: the Gambian PRP-T Hib conjugate trial — 100% efficacy against culture-positive Hib pneumonia (0 vs 10 cases) and 21.1% against radiologically defined pneumonia, suggesting about 20% of radiological pneumonia in Gambian children was due to Hib.^[13]
• Watt Lancet 2009 and Wahl Lancet Glob Health 2018: quantified the Hib and pneumococcal pneumonia burden in unvaccinated vs vaccinated settings.^[10][11]
• de Benedictis Lancet 2020: a comprehensive review of complicated pneumonia in children.^[21]
• PERCH Lancet 2019: multi-country case-control study at nine sites in seven countries (4232 cases, 5119 controls); blood cultures were positive in only 3.2% with S pneumoniae the commonest isolate; 30-day case-fatality 6.4%.^[5]
• St Peter 2009 (J Pediatr Surg): VATS vs chest tube + fibrinolysis (12F tube, 4 mg tPA instillations) in paediatric empyema — no difference in post-intervention hospital days, oxygen days, or days to afebrile.^[18]
• Rahman NEJM 2011 (MIST2): in adult pleural infection, 3 days of intrapleural tPA + DNase improved pleural-opacity clearance versus placebo and reduced surgical referral, while neither agent alone differed from placebo; paediatric fibrinolysis evidence comes from trials such as St Peter's.^[19]
• Waites 2004 Clin Microbiol Rev and Kutty 2019 Clin Infect Dis: comprehensive reviews of Mycoplasma pneumoniae in children — clinical, diagnostic, and treatment considerations.^[16][17]
• Roberts BTS 2023 Thorax: full BTS pleural disease guideline.^[20]
• Nair Lancet 2010: quantified RSV's share of global childhood pneumonia.^[4]
• Li Lancet 2022 + GBD 2019/2021 Collaborators: the GBD series as the source of contemporary mortality numbers.^[1][2][3]
• Italian Intersociety Consensus (Donà Ital J Pediatr 2024): clinical pathways for mild-to-moderate CAP in previously healthy children.^[23]

Guidelines

• WHO Pocket Book of Hospital Care for Children, 2nd ed. 2013 — bedside reference for pneumonia management in hospitals.^[24]
• WHO IMCI/IMNCI chart booklet — first-level facility framework.
• BTS adult CAP guideline (Lim Thorax 2009) — adult-specific, but cross-cutting principles apply.^[9]
• Italian Pediatric Intersociety Consensus (Dona Ital J Pediatr 2024) — example of national paediatric consensus.^[23]

Regional deltas

Controversies

• Corticosteroids in childhood pneumonia — meta-analyses in adults show benefit; paediatric evidence is mixed; not routine, considered for severe hypoxaemic pneumonia on a case-by-case basis.
• Vitamin A supplementation — WHO recommends in measles and severe acute malnutrition; routine supplementation in pneumonia without measles/SAM has limited benefit.
• Duration of antibiotic course — 3 days may be non-inferior to 5 days for non-severe pneumonia (green-IMCI Kenya data); 5-7 days remains the mainstream MBBS/NEET-PG approach.
• Criteria for HFNC vs CPAP vs early IMV in severe pneumonia — under active trial.^[7]

Exam Pearls

A high-yield summary designed for last-minute revison.^[24]

• Pneumonia is a leading infectious killer of under-5s: it accounts for 15% of all under-five deaths globally.^[27]
• WHO operational definition: cough or difficulty breathing with fast breathing.
• Fast breathing is age-related: WHO-approved signs are age-related fast breathing and lower chest wall indrawing; respiratory rate over 50/min and over 40/min are the classic examined thresholds — no single feature is sufficient alone (pooled sensitivity of fast breathing 0.62).^[28]
• Lower chest wall indrawing = severe pneumonia → hospitalise.
• WHO danger signs = very severe pneumonia: inability to drink, convulsions, vomiting everything, severe malnutrition, grunting → emergency care.
• Leading viral cause under 1 year = RSV.^[4][15]
• Leading bacterial cause overall = Streptococcus pneumoniae (still, despite PCV).
• Hib pneumonia has fallen dramatically with the introduction of conjugate vaccine.^{[10][11][13][14]}
• Mycoplasma pneumoniae = most common cause of CAP in school-age (>5 yr) children; macrolide is the antibiotic.^[16][17]
• PVL-positive Staph aureus in children: pneumatocele, empyema, necrotising pneumonia; cover with vancomycin/linezolid empirically.^[21]
• Oral amoxicillin 80-90 mg/kg/day in two doses × 5 days for WHO pneumonia — home therapy equivalent to hospital parenteral ampicillin (Hazir SAT).^[8]
• Severe pneumonia (hospital option): parenteral ampicillin 100 mg/kg/day in four doses for 48 h, then oral amoxicillin to complete.^[8]
• Chest-indrawing pneumonia without danger signs: outpatient oral amoxicillin is WHO-endorsed (2024 update).^[24]
• SpO2 under 90% = hypoxaemia → give oxygen; hypoxaemia is the strongest predictor of death in severe pneumonia (adjusted OR 11.1).^[27]
• Non-response at 48-72 h → investigate complicated pneumonia (effusion, empyema, necrotising pneumonia, abscess).^[21]
• MIST2: 3 days of intrapleural tPA + DNase (not either agent alone) improves drainage in pleural infection.^[19]
• VATS (video-assisted thoracoscopic surgery) if fibrinolysis fails.
• PCV13/PCV10 + Hib + measles + annual influenza are the four most important vaccines.
• Neonatal chlamydial pneumonia: maternal C. trachomatis causes conjunctivitis and pneumonia despite ocular prophylaxis — antenatal maternal screening and treatment is the effective strategy.^[30]
• RSV bronchiolitis ≠ pneumonia, but both can coexist; treatment of bronchiolitis is supportive.
• Bordetella pertussis in infants: paroxysms, whoop, lymphocytosis, apnoeas → macrolide.
• Staphylococcal pneumonia (post-influenza): pneumatoceles, empyema, necrotising pneumonia.
• Severe malnutrition with pneumonia: hypoxaemia remains the strongest mortality predictor — screen with pulse oximetry.^[27]
• HIV: co-trimoxazole prophylaxis (from 4-6 weeks of age in HIV-exposed infants) prevents Pneumocystis pneumonia.^[29]
• Antibiotics NOT routine in viral URTI; only indicated in pneumonia meeting WHO severity criteria.

Exam application bank (NEET-PG / INICET)

One-line answer

Pneumonia in children = inflammation of the lung parenchyma, the single leading infectious cause of under-5 mortality globally, responsible for ~700,000 deaths/year (≈14% of all under-5 deaths). The WHO operational definition is cough or difficulty breathing with fast breathing defined by age (over 50/min at 2-12 months, over 40/min at 12 months-5 years, over 20/min at over 5 years). WHO classifies severity into pneumonia (fast breathing only, treat at home with oral amoxicillin), severe pneumonia (lower chest wall indrawing, hospitalise), and very severe pneumonia (danger signs: inability to drink, convulsions, vomiting everything, severe malnutrition, grunting — IV/IM antibiotics urgently). Leading viral cause under 1 year = RSV. Leading bacterial cause = Streptococcus pneumoniae; Hib pneumonia has fallen dramatically with conjugate vaccination. Empirical treatment: oral amoxicillin 80

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard.^[7]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes.^[21]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change.^[12]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each.^[24]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory.^[24]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Pneumonia in Children.

References31ShowHide

1. [1]Li Y, Wang X, Blau DM, et al; GBD 2019 LRI Collaborators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2019: a systematic analysis. Lancet, 2022.PMID 35598608
2. [2]GBD 2019 Lower Respiratory Infections Collaborators. Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019. Lancet Infectious Diseases, 2022.PMID 35964613
3. [3]GBD 2021 Lower Respiratory Infections Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies in 2021, with forecasts to 2050: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infectious Diseases, 2024.PMID 38636536
4. [4]Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010.PMID 20399493
5. [5]Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet, 2019.PMID 31257127
6. [6]Deloria Knoll M, Prosperi C, Baggett HC, et al. Introduction to the Site-specific Etiologic Results From the Pneumonia Etiology Research for Child Health (PERCH) Study. Pediatric Infectious Disease Journal, 2021.PMID 34448739
7. [7]Hazir T, Qazi SA, Bin Nisar Y, et al. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2-59 months: a randomised equivalence trial. Archives of Disease in Childhood, 2007.PMID 16547082
8. [8]Hazir T, Fox LM, Nisar YB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet, 2008.PMID 18177775
9. [9]Rothberg MB Community-Acquired Pneumonia. Annals of internal medicine, 2022.PMID 35404672
10. [10]Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet, 2009.PMID 19748399
11. [11]Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccine: global estimates. Lancet Global Health, 2018.PMID 29903376
12. [12]Farrar JL, Childs L, Ouattara M, et al. A systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults and elderly patients. Pathogens, 2023.PMID 37242402
13. [13]Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia. Lancet, 1997.PMID 9130939
14. [14]de Andrade AL, de Andrade JG, Martelli CM, et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. International Journal of Epidemiology, 2004.PMID 15075166
15. [15]Manzoni P, Figueras-Aloy J, Simões EAF, et al. Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases. Infectious Diseases and Therapy, 2017.PMID 28653300
16. [16]Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clinical Microbiology Reviews, 2004.PMID 15489344
17. [17]Kutty PK, Jain S, Taylor TH, et al. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clinical Infectious Diseases, 2019.PMID 29788037
18. [18]St Peter SD, Tsao K, Spilde TL, et al. Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. Journal of Pediatric Surgery, 2009.PMID 19159726
19. [19]Rahman NM, Maskell NA, West SE, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine, 2011.PMID 21830966
20. [20]Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society Guideline for pleural disease. Thorax, 2023.PMID 37433578
21. [21]de Benedictis FM, Kerem E, Chang AB, et al. Complicated pneumonia in children. Lancet, 2020.PMID 32919518
22. [22]Hanquet G, Krizova P, Valentiner-Branth P, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax, 2019.PMID 30355641
23. [23]Donà D, Brigadoi G, Grandinetti R, et al. Treatment of mild to moderate community-acquired pneumonia in previously healthy children: an Italian intersociety consensus. Italian Journal of Pediatrics, 2024.PMID 39427174
24. [24]Kundu S, Das S, Medhagopal RG An Update on WHO Recommendations on Childhood Pneumonia and Diarrhea (2024). Indian pediatrics, 2025.PMID 40839064
25. [25]D'Souza RM, D'Souza R. Vitamin A for treating measles in children. Cochrane Database of Systematic Reviews, 2002.PMID 11869601
26. [26]Singhi SC, Baranwal AK, Guruprasad, et al. Potential risk of hypoxaemia in patients with severe pneumonia but no hypoxaemia on initial assessment: a prospective pilot trial. Paediatrics and International Child Health, 2012.PMID 22525444
27. [27]Rahman AE, Hossain AT, Chisti MJ, et al. Hypoxaemia prevalence and its adverse clinical outcomes among children hospitalised with WHO-defined severe pneumonia in Bangladesh. Journal of Global Health, 2021.PMID 34552722
28. [28]Rambaud-Althaus C, Althaus F, Genton B, et al. Clinical features for diagnosis of pneumonia in children younger than 5 years: a systematic review and meta-analysis. Lancet Infectious Diseases, 2015.PMID 25769269
29. [29]Church JA, Fitzgerald F, Walker AS, et al. The expanding role of co-trimoxazole in developing countries. Lancet Infectious Diseases, 2015.PMID 25618179
30. [30]Smith-Norowitz TA, Ukaegbu C, Kohlhoff S, et al. Neonatal prophylaxis with antibiotic containing ointments does not reduce incidence of chlamydial conjunctivitis in newborns. BMC Infectious Diseases, 2021.PMID 33731049
31. [31]Graham HR, Bakare AA, Ayede AI, et al. Cost-effectiveness and sustainability of improved hospital oxygen systems in Nigeria. BMJ Global Health, 2022.PMID 35948344